Navigation Links
Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma
Date:12/16/2009

About Special Protocol Assessments

The Special Protocol Assessment (SPA) process is a procedure by which the FDA provides official evaluation and written guidance on the design and size of proposed protocols that are intended to form the basis for a new drug application.

Final marketing approval depends on the results of efficacy, the adverse event profile and an evaluation of the benefit/risk of treatment demonstrated in the Phase 3 trial. The SPA agreement may only be changed through a written agreement between the sponsor and the FDA, or if the FDA becomes aware of a substantial scientific issue essential to product efficacy or safety. For more information on Special Protocol Assessment, please visit: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm080571.pdf

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits the phosphoinositide 3-kinase (PI3K)/Akt pathway, a key signaling cascade that has been shown to induce cell growth and cell transformation. KRX-0401 has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with novel therapies. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK pathway, which are pathways associated with programmed cell death, cell growth, ce
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
2. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
3. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
4. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
5. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
6. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
7. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
8. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
9. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
10. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
11. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... 22, 2013 The new 13-valent pneumococcal conjugate ... previous version used prior to 2010, the 7-valent pneumococcal ... published today in Vaccine. The U.S. Food ... 2010 after a series of trials. These trials found ... pneumococcal types than the previously used PCV7, did not ...
(Date:5/22/2013)... May 22, 2013  Healthcare providers are ... content management (ECM) solution, for a ... System .  These organizations identified enterprise content ... will use OnBase to optimize their Meditech ... (Logo:  http://photos.prnewswire.com/prnh/20090130/65710LOGO  ) ...
(Date:5/22/2013)... , 22. Mai 2013 Kepner-Tregoe ... Beratung, gab heute bekannt, dass der Veteran ... , zum Hauptgeschäftsführer ernannt wurde. Geraghty,s ... Industriebereich wo er zahlreiche Führungspositionen bei Fertigungsunternehmen ... Baxter an, der als Kepner-Tregoe Hauptgeschäftsführer gedient ...
Breaking Medicine Technology:Kaiser Permanente Study Finds New Pneumococcal Vaccine Appears to be as Safe as Previously Used Vaccine 2Kaiser Permanente Study Finds New Pneumococcal Vaccine Appears to be as Safe as Previously Used Vaccine 3Kaiser Permanente Study Finds New Pneumococcal Vaccine Appears to be as Safe as Previously Used Vaccine 4Three New Health Systems Integrate Hyland Software's OnBase with Meditech Hospital Information System 2Three New Health Systems Integrate Hyland Software's OnBase with Meditech Hospital Information System 3Kepner-Tregoe, Inc. befördert Chris Geraghty zum Hauptgeschäftsführer 2Kepner-Tregoe, Inc. befördert Chris Geraghty zum Hauptgeschäftsführer 3
(Date:5/22/2013)... May 22, 2013 DePuy Pinnacle ... DePuy Pinnacle Hip Replacement System continue to move forward ... Bernstein Liebhard LLP reports. According to an Order ... to produce monitoring reports associated with a 2007 criminal ... device marketing practices. Plaintiffs maintained in their ...
(Date:5/22/2013)... 22, 2013 Today, Zane Benefits, Inc. ... Insurance Exchange . Zane Benefits, which provides comprehensive and ... the leader in defined contribution plans and ... Benefits’ website, beginning in 2014 as part of the ... and small businesses will become available through new state ...
(Date:5/22/2013)... that hospitals may be reaping enormous income for ... bloodstream infections contracted in their intensive care units. ... in the American Journal of Medical Quality ... who develops an avoidable central line-associated bloodstream infection ... for than a similar infection-free patient. Moreover, hospitals ...
(Date:5/22/2013)... 2013 Registered Dietitian and Founder of Tatalou ... Tatalou.com sharing a recipe for making energy bars at home. ... Bars ,” takes a recipe modified from one recently ... “Every day it gets more and more difficult to understand ... “The size of the nutrition label continues to grow and ...
(Date:5/22/2013)... (PRWEB) May 22, 2013 Unknown to the ... area at 30 mph. Minutes before it struck, the ... the nearing threat. This gave them time to reach safety ... Data is proud to provide a product that will ... A Wheelock SAFEPATH® SP40S Emergency Evacuation System provides ...
Breaking Medicine News(10 mins):Health News:DePuy Pinnacle Lawsuit News: Bernstein Liebhard LLP Notes New Order in Federal Pinnacle Litigation Requiring Production of Monitoring Reports from Federal Investigation 2Health News:DePuy Pinnacle Lawsuit News: Bernstein Liebhard LLP Notes New Order in Federal Pinnacle Litigation Requiring Production of Monitoring Reports from Federal Investigation 3Health News:Zane Benefits Publishes New Information on Alabama Health Insurance Exchange 2Health News:Zane Benefits Publishes New Information on Alabama Health Insurance Exchange 3Health News:Hospitals profit when patients develop bloodstream infections 2Health News:Hospitals profit when patients develop bloodstream infections 3Health News:Hospitals profit when patients develop bloodstream infections 4Health News:How To "Make Your Own Healthy Energy Bars" 2Health News:Telcom & Data Introduces Wheelock SAFEPATH® SP40S Emergency Evacuation System, An Effective Office Tool to Protect Employees from Severe Weather Threats 2
... Feb. 20 /Xinhua-PRNewswire/ -- Venture Global Limited,unveils the ... pollution. With VEGO Power Blocker, cellphone users could ... Be Protected, VEGO Power Blocker Kills the Invisible ... VEGO Power Blocker is a piece of ultra-thinned ...
... first scientific evidence that deadly emerging diseases have ... the outbreaks main sources. They say new diseases ... the greatest threat to humans. Expansion of humans ... with wildlife are the reason, they say. Meanwhile, ...
... Anti-bleeding agent Trasylol tied to increased death, complications, studies ... new studies confirm an increased incidence of death and ... used to reduce bleeding during coronary artery bypass surgeries. ... over both the short- and long-term. , Trasylol,s German ...
... , , WEDNESDAY, Feb. 20 (HealthDay News) -- The time of day ... the difference between life and death. , Two new studies find ... weekends are more likely to die in the hospital than those ... acceptable, one researcher said. "We should not be treating patients ...
... heart disease had no ... risk factors, BALTIMORE, Feb. 20 In an effort to ... Foundation will,hold its annual Women,s Heart Health Fair on Tues., Feb. ... Mayor Sheila,Dixon has granted non-essential female workers two hours leave that ...
... put an end to toothaches, PHILADELPHIA, Feb. ... model, based in Philadelphia, announced that it is,expanding ... offering licensing,opportunities to qualifying dental practices, worldwide. This ... in advancing,affordable dental/health care available everywhere, to all., ...
Cached Medicine News:Health News:Venture Global Limited Introduces an Innovative Anti-Cellphone Radiation Sticker Named 'VEGO Power Blocker' 2Health News:Scientists make first map of emerging-disease hotpsots 2Health News:Scientists make first map of emerging-disease hotpsots 3Health News:More Evidence of Danger From Heart Surgery Drug 2Health News:More Evidence of Danger From Heart Surgery Drug 3Health News:In-Hospital Stroke Deaths Rise on Nights, Weekends 2Health News:In-Hospital Stroke Deaths Rise on Nights, Weekends 3Health News:Free Health Screenings Aim to Identify Risk of Heart Disease in Women 2Health News:Emergency Dentist 24/7(TM) Announces Worldwide Licensing Program 2
Stat Detection of Soluble Fibrin Monomer Complexes by the Hemagglutination Technique, 32 tests....
For use with catalog #0540....
Immuno-turbidimetric Assay of D-Dimer by STA© Analyzers. Microlatex particles coated with two different mouse monoclonal anti-human D-Dimer antibodies....
Antigenic Free Protein S, ELISA Method...
Medicine Products: